Ensysce Biosciences (NASDAQ:ENSC – Get Free Report) is expected to be announcing its earnings results before the market opens on Friday, March 21st.Analysts expect the company to announce ...

Ensysce Biosciences (ENSC) will host a symposium on Wednesday, September 3, 2025, during PAINWeek 2025, designed to share perspectives with ...

ENSC READ THE FULL ENSC RESEARCH REPORT Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities ...

Ensysce Biosciences (NASDAQ:ENSC) is a clinical stage company that is developing treatments designed to have the same pain-relieving capabilities as opioids but come with the ability to inhibit ...

Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 /Ensysce ...

Investment analysts at Zacks Small Cap reduced their Q1 2025 EPS estimates for shares of Ensysce Biosciences in a research report issued to clients and investors on Tuesday, March 11th. Zacks Small ...

Data is not available at this time. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is ...

This course is taught together with ENSC 427. Please refer to the ENSC 427 web page for details. Current count of email messages related to ENSC 894 exchanged this term: 124. Course description: This ...

Ensysce Biosciences (NASDAQ:ENSC) released its 4Q2024 results that showed a good cash balance of $3.5 million due in large part to the financing activities management has undertaken which we’ve ...

Analgesic Experts Consider Pain Indications Versus New Classes of Analgesics ~ ~ Panel Discussion Posted to Ensysce's Corporate Website ~ SAN DIEGO, CA / ACCESS Newswire / March 18, 2025 /Ensysce ...